HRD Test, BRACAnalysis Predict Platinum-based Treatment Benefit in Early-Stage, Advanced TNBC | GenomeWeb

SAN ANTONIO – Using Myriad Genetics' next-generation sequencing based homologous recombination deficiency (HRD) Test, researchers have identified a subset of early-stage triple-negative breast cancer (TNBC) patients who responded to platinum-based therapies, according to data presented at the San Antonio Breast Cancer Symposium.

Additionally, in a separate study presented here, this time in advanced TNBC patients, researchers reported that BRCA mutation status gauged by Myriad's BRACAnalysis test was predictive of carboplatin benefit over docetaxel.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.